Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Status:
Recruiting
Trial end date:
2025-01-17
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and
pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody
(mAb) in participants with advanced malignancies.
This study consists of 2 parts:
Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in
Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.